Company Description
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia.
Scienture Holdings, Inc. is headquartered in Commack, New York.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 13, 2020 |
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Shankar Hariharan |
Contact Details
Address: 20 Austin Boulevard Commack, New York 11725 United States | |
| Phone | 631) 670-6039 |
| Website | scienture.com |
Stock Details
| Ticker Symbol | SCNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1382574 |
| CUSIP Number | 80880X104 |
| ISIN Number | US80880X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Narasimhan Mani M.B.A., Ph.D. | President, Co-Chief Executive Officer and Director |
| Dr. Shankar Hariharan Ph.D. | Founder, Co-Chief Executive Officer and Executive Chairman |
| Eric Michael Sherb C.P.A. | Chief Financial Officer |
| Rahul Surana M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer of Scienture LLC |
| Michele Rath | Senior Vice President and Chief Commercial Officer of Scienture LLC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 5, 2026 | 8-K | Current Report |
| May 1, 2026 | 8-K | Current Report |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Mar 30, 2026 | 10-K | Annual Report |
| Nov 18, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | 424B5 | Filing |